Neurotech industry giants and investors returning to Helsinki

Report this content

– the 2ndEuropean Neurotech Investing and Partnering Summit, September 4-5,  2013

Press release August 19 2013

Location: Scandic Grand Marina and Congress Center, Helsinki

Neurotech giants revisit Helsinki for the 2ndEuropean Neurotech Investing and Partnering Summit on September 4-5, 2013. Major health players such as Merck, Medtronic, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Johnson & Johnson, and UCB Pharma are coming to learn about the latest research developments and business opportunities that Europe has to offer. Over forty executives will present the latest treatments in their pipelines for Alzheimer's, addiction, anxiety, depression, pain, sensory disorders, obesity, stroke, schizophrenia, sleep disorders, epilepsy, multiple sclerosis, traumatic brain injury, spinal cord injury, Parkinson's and more.

"The successful launch of the first European Neurotech Investing and Partnering Summit in 2011 and the growing interests of the industry have led us to organize the summit for the second time in Europe. As a testament to the growing opportunities in the space, a sizable group of new public and private investors are attending including Action Potential Venture Capital, LundbeckFond, Novo Seeds, and Sofinnova Partners. Additionally, many of the top European investors are participating again such as Early Bird Ventures, HealthCap, Oxford Finance, and TVM Capital," says Casey Lynch, Managing Director of NeuroInsights, the organizer of the event.

Neurotechnology, encompassing over 800 companies worldwide developing drugs, devices and diagnostics for brain and nervous system illnesses, generated over €116 billion annual revenues in 2012. While over 2 billion people are afflicted with brain-related illnesses, only a small portion of them is currently receiving effective treatment.  Advances in drugs, devices and diagnostics are coming quickly, however.  

“We are expecting international investors, global neurotech companies and Europe’s top researchers and entrepreneurs to find business opportunities together. To have the summit again in Helsinki also provides a superb showcase for the Finnish health technology community. This week is actually quite unique as there is another related conference being held, namely the MedTech Nordic Investing & Partnering on September 3rd. Helsinki is clearly becoming a life science hub and hot spot in Europe.” shares CEO Micah Gland from Helsinki Business Hub, a partner of both events.  

---

European Neurotech Investing and Partnering Summit

This inaugural summit features keynotes on the state of the European neurotech industry, cutting edge company presentations, leading investor analysis, outstanding translational research projects, and panel discussions on a comprehensive selection of topics.

Registration: www.neurotecheu2013.com

NeuroInsights

NeuroInsights, the world-leading neurotech market authority, organizer of the conference with the Neurotechnology Industry Organization, a trade association of over 100 leading companies, venture capital firms, patient advocacy groups, and research institutes. www.neuroinsights.com, www.neurotechindustry.org 

Contact person: Zack Lynch, zack@neurotechindustry.org

Helsinki Business Hub

Helsinki Business Hub is the investment promotion agency for the Greater Helsinki. Funded by public sources -  the cities of Helsinki, Espoo, Vantaa and Kauniainen as well as the Uusimaa Regional Council - Helsinki Business Hub identifies business opportunities for international companies and helps them thrive in the heart of business in Finland, Russia and the Baltics. www.helsinkibusinesshub.fi 

Contact person: Indrek Tammeaid, indrek.tammeaid@helsinkibusinesshub.fi

Media contact person:

YC Felin, yc.felin@helsinkibusinesshub.fi, +358 45 134 1336

Documents & Links